Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants

  1. F. Javier Ibarrondo
  2. Christian Hofmann
  3. Ayub Ali
  4. Paul Ayoub
  5. Donald B. Kohn
  6. Otto O. Yang

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

As SARS-CoV-2 evolves to become better suited for circulating in humans, mutations have occurred in the spike protein it uses for attaching to cells it infects. Protective antibodies from prior infection or vaccination target the spike protein to interfere with its function.

Article activity feed

  1. Version published to 10.1128/mbio.02656-21
  2. ScreenIT

    SciScore for 10.1101/2021.08.27.21262744: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsConsent: Participants: Volunteers provided informed consent under an institutional review board-approved protocol.
    IRB: Participants: Volunteers provided informed consent under an institutional review board-approved protocol.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    In brief, we utilized a modification of a previously reported ELISA [8-10] against recombinant receptor binding domain (RBD) protein bound to a 96-well microtiter plate, using secondary goat anti-human IgG-, IgM-, or IgA-horseradish peroxidase-conjugated detector antibodies.
    anti-human IgG-
    suggested: (GenWay Biotech Inc. Cat# 20-783-75007-0.2 mg, RRID:AB_1023061)
    IgA-horseradish peroxidase-conjugated detector antibodies.
    suggested: None
    For quantitation, each plate contained serial dilutions of the CR3022 monoclonal antibody in IgG, IgM, or IgA formats, and the amount of binding activity in serum was expressed as an equivalent amount of the control antibody.
    CR3022
    suggested: None
    The “neutralizing potency” (neutralizing activity adjusted for antibody concentration) was defined as the ratio of neutralization activity (DF80) to anti-RBD antibody concentration (log10 sum of IgG, IgM, and IgA anti-RBD antibodies in ng/ml), adjusting neutralizing activity for antibody quantity.
    DF80
    suggested: None
    anti-RBD
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    The assay was performed by adding serial dilutions of serum during infection of ACE2-expressing HEK 293T cells and assessing luciferase activity after 48 hours.
    HEK 293T
    suggested: None

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.08.27.21262744v1 on medRxiv